Mazdutide

Mazdutide, also known as IBI362 or LY3305677, is a once-weekly dual glucagon receptor and GLP-1 receptor agonist developed for metabolic disease. The strongest evidence is in Chinese adults with overweight, obesity, or type 2 diabetes. A phase 2 randomized trial found clinically meaningful weight reduction over 24 weeks, while GLORY-1, a phase 3 trial in Chinese adults with overweight or obesity, reported significant body-weight reductions over 32 and 48 weeks. Separate phase 2 and phase 3 diabetes trials found HbA1c lowering and weight reduction compared with placebo. The evidence base is relatively strong for studied populations, but generalizability outside those trial populations should be stated cautiously.

Weight-Management Trials

Mazdutide produced dose-dependent body-weight reductions versus placebo in a 24-week phase 2 trial and clinically relevant weight reduction in GLORY-1 ^[1][3].

Type 2 Diabetes Trials

In Chinese adults with type 2 diabetes, mazdutide reduced HbA1c and body weight versus placebo in phase 2 and phase 3 trials ^[2][4].

Population Boundary

Trials were conducted primarily in Chinese populations; claims should stay population-specific unless broader evidence is added ^[1][3][4].

Gastrointestinal Tolerability

The most common adverse events in mazdutide trials were gastrointestinal, including diarrhea, nausea, decreased appetite, and vomiting ^[1][4].

Cardiometabolic Follow-Up

Heart-rate changes and broader cardiovascular effects require longer-term evaluation for dual GLP-1/glucagon agonists ^[1].